PI3K/APC pathway and cyclin-dependent kinase pathway to predict complete responders in CRC patients treated with ADAPT therapy.

e14642 Background: Recent studies have demonstrated that aspirin or selective COX-2 inhibitor improves overall survival in colorectal cancer (CRC) patients with PIK3CA mutations. However, routine use of anti-inflammatory agents in metastatic CRC patients remains controversial. We showed that addition of celecoxib, a selective COX-2 inhibitor coupled with capecitabine in a two step ADAPT (activating dormant tumor cells and potentiate targeting) therapy led to complete responses (CR) and long-term survival in patients with stage IV CRC. We sought to determine genetic aberrations and related pathways as predictor of CR to ADAPT therapy. Methods: We retrospectively reviewed 54 ADAPT therapy treated patients with stage IV CRC patients and tested for a panel of 199 cancer-related genes (UW Oncoplex) with Illumina deep sequencing platform between 2002-2012 including 11 CR for chemo, 12 CR for chemo-radiation, and surgical CR patients (none CR). The median overall survival in these CR patients had reached 92.7 mo...